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Objectives. We sought o compare in-hospital and long-term 
outcome after angioplasty in patients with single-, double- and 
triple-vessel disease. 
Background. Coronary angioplasty is increasingly used in 
patients with multivessel disease. 
Methods. The source of data was the clinical data base at 
Emory University. Patients who had previous coronary revascu- 
larization or who underwent angioplasty in the setting of acute 
myocardial infarction were excluded. 
Results. Of 10,783 patients, 71% had one-vessel, 24% two-vessel 
and 5% three-vessel disease. Age, male gender, diabetes, hyper- 
tension, history of previous myocardial infarction, Canadian 
Cardiovascular Society class III or IV angina and congestive 
failure all increased with severity of disease. Complete revascu- 
larization was achieved in most patients with one-vessel disease, 
in a minority with two-vessel disease and rarely in those with 
three-vessel disease. Emergency coronary bypass surgery in- 
creased from 1.7% with one-vessel disease to 3.2% with three- 
vessel disease. Q wave myocardial infarctions could not be shown 
to vary significantly with severity of disease. The mortality rate 
increased from 0.2% with one-vessel disease to 1.2% with three- 
vessel disease. The number of vessels diseased was a multivariate 
correlate of in-hospital and long-term mortality. The 1-, 5- and 
10-year survival was 0.99, 0.93 and 0.86 for one-vessel disease and 
0.97, 0.89 and 0.76 for two-vessel disease, respectively. The 1-, 5- 
and 9-year survival was 0.95, 0.85 and 0.70 in three-vessel disease, 
respectively. Freedom from myocardial infarction, coronary by- 
pass surgery and repeat angioplasty was also lower with more 
severe disease. 
Conclusions. Patients have increasing in-hospital and long- 
term mortality as the severity of disease increases. There is also 
an increased incidence of myocardial infarction and revascular- 
ization procedures with more severe disease. 
(J Am CoU Cardiol 1995;26:142-51) 
Since its introduction in 1977 (1), coronary angioplasty has 
become the most common form of myocardial revasculariza- 
tion (2). Increased use of angioplasty in patients with multives- 
sel disease has broadened the population i  whom this proce- 
dure is performed. The appropriate utilization of this 
procedure in patients with multivessel disease is unclear be- 
cause there is uncertainty asto which patients will benefit most 
from angioplasty, which from coronary surgery and which from 
medical therapy. Clinical outcome series can supplement the 
medical decision-making process that will come out of clinical 
trials by providing an in-depth perspective in a large number of 
patients. This report describes the long-term outcome of 
patients after coronary angioplasty. 
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Methods  
Patient population. From June 1980 through December 
1991, 10,785 patients without previous angioplasty or coronary 
surgery underwent angioplasty either electively or emergently 
for unstable angina performed at Emory University Hospitals. 
The number of vessels diseased could not be determined in two 
patients, leaving 10,783 in the study population. Included were 
patients undergoing elective angioplasty for stable or unstable 
angina pectoris or after several days of stabilization after acute 
myocardial infarction. In patients with uncontrolled unstable 
angina at the time of angioplasty, the procedure was consid- 
ered emergent for unstable angina. Those who had the proce- 
dure performed emergently in the setting of infarction were 
excluded. 
Definitions. Single-vessel disease = presence of ->50% di- 
ameter lumen narrowing in either the left anterior descending, 
left circumflex or right coronary artery or a major branch or 
branches; double-vessel disease = presence of ->50% diameter 
lumen narrowing in two of the three major epicardial vessel 
systems; three-vessel disease = presence of ->50% diameter 
lumen narrowing in all three major epicardial vessel systems or 
in the left anterior descending and proximal circumflex in 
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coronary arteries left dominant patients; angiographicaIly suc- 
cessful angioplasty = in all lesions attempted, improvement 
>20% in diameter stenosis and dilated to <50% residual 
diameter stenosis; clinically successful angioplasty - angio- 
graphic success without complications of myocardial infarc- 
tion, coronary surgery or death during the same hospital 
period; complete revascularization = dilation of all obstructions 
>50% narrowed in vessels >1.5 mm in diameter to <50% 
narrowed and by more than absolute 20% of the normal zone; 
variables defined by patient his'to O, = hypertension, diabetes, 
severity of angina, previous myocardial infarction, myocardial 
infarction during follow-up. Angina was defined according to 
the Canadian Cardiovascular Society Classification (3) and 
congestive heart failure according to New York Heart Associ- 
ation criteria. Unstable angina was diagnosed as chest pain 
consistent with angina that increased in frequency or duration 
of episodes within 3 months. 
Procedure and data collection. All angioplasty procedures 
were performed using previously described standard tech- 
niques (4). Baseline and restudy demographic, linical, anglo- 
graphic and procedural data, including complications, were 
recorded prospectively on standardized forms and entered into 
a computerized data base. All fields are defined in a data 
dictionary. The preangioplasty, postangioplasty and restudy 
angiograms were measured with validated digital electronic 
calipers (Sandhill Scientific Inc. after 1983, with a prototype 
[1981 to 1983]) (5) or by hand-tracing (1980 to 1981) by 
experienced angiographers involved in the procedure but other 
than the primary operator. The angiographic measurements 
were calibrated to the size of the catheter. The degree of 
narrowing of each coronary artery lesion was expressed as the 
percent diameter narrowing of the abnormal segment com- 
pared with the normal adjacent arterial segments. The diam- 
eter stenosis recorded was the mean value determined in two 
views. These measurements were performed as an ongoing 
clinical activity and were not blinded to clinical data. 
Patient follow.up. Follow-up information was obtained 
from the patients or their referring physicians. Follow-up 
status for each end point was also assessed at each subsequent 
hospital admission. Patients not readmitted were contacted by 
telephone or letter. Follow-up was available for 10,108 (94%) 
of the 10,783 patients. The mean length of follow-up was 3.5 + 
2.8 years. Information obtained included occurrence of myo- 
cardial infarction since the initial angioplasty, subsequent eed 
for an additional revascularization procedure (angioplasty or 
coronary, surgery), death (cardiac plus noncardiac) and recur- 
rent angina. All follow-up information was recorded on stan- 
dardized forms and entered into the computerized data base. 
All repeat procedures performed at Emory University Hospi- 
tals were confirmed from the data base. Myocardial infarctions 
during follow-up were ascertained largely from the patients; 
thus, there may have been both under and overreporting. 
Statistical analysis. Data are expressed as proportions or 
mean value + SD. Differences in categoric variables were 
analyzed by chi-square analysis (or Fisher exact test), and 
differences in continuous variables were analyzed by Student t 
tests. The clinical, angiographic and procedure characteristics 
of each group were determined. Correlates of in-hospital death 
were determined by logistic regression. Overall survival (car- 
diac plus noncardiac) and event-free survival were determined 
by the Kaplan-Meier method (6), and the estimated probability 
is shown together with the standard error of the estimate. 
Overall survival and event-free survival analyses were per- 
formed for the total population as well as for subgroups. End 
points analyzed included 1) survival, 2) freedom from myocar- 
dial infarction, 3) freedom from coronary artery bypass ur- 
gery, and 4) freedom from repeat angioplasty. Comparisons of 
total and event-free survival were made using the Mantel-Cox 
method (7). Multivariate correlates of survival were analyzed 
with Cox model analysis (8). The analyses, both logistic 
regression and Cox model, were repeated with variables that 
were frequently eliminated to determine the impact of missing 
data (and, consequently, fewer patients in the model) on the 
analyses. Colinearity between variables was examined. Ejec- 
tion fraction and height had a considerable number of missing 
values (in 31% and 14%, respectively), which resulted in the 
in-hospital model of death considering only 16 deaths. Values 
input for missing data were determined by linear regression 
and used in the model to increase the number of patients and 
deaths (to 28). Imputation of height was modeled as a function 
of age, congestive heart failure, hypertension and gender. 
Imputation of ejection fraction was modeled with gender, 
congestive heart failure, previous myocardial infarction, angina 
class and vessels diseased as covariates. 
Resu l ts  
Clinical characteristics. Of 10,783 patients, 71% had one- 
vessel disease, 24% had two-vessel disease, and 5% had 
three-vessel disease. The percent of patients with multivessel 
disease has increased, such that the percent of patients with 
two- and three-vessel disease increased from 10.7% and 0.9% 
of patients undergoing dilation during 1980 to 1983, to 25.0% 
and 5.7% during 1984 to 1989 and to 32.6% and 8.7% during 
1990 to 1991 (p < 0.0001). Age increased as the number of 
diseased vessels increased (p < 0.0001, two- vs. three-vessel 
disease) (Table 1). Although 28% of patients with one- 
vessel disease were women, only 21% of patients with 
three-vessel disease were women. Diabetes almost doubled 
in frequency, from 12% in one-vessel disease, to 16% in 
two-vessel and to 23% in three-vessel disease (p < 0.0001, two- 
vs. three-vessel disease). The frequency of hypertension, history 
of previous myocardial infarction, class III or IV angina and 
congestive failure all increased with severity of disease. Emergent 
cases for uncontrolled unstable angina were unusual. 
Angiographic characteristics and outcome. Ejection frac- 
tion was slightly lower in more severe disease (Table 2). Artery 
size, and diameter stenosis before and after angioplasty varied 
slightly with severity of disease. The left anterior descending 
coronary artery and its proximal portion were dilated more 
frequently insingle- than in multivessel disease. The frequency 
of multisite dilations was 15% for one-vessel disease, 43% for 
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Table 1. Clinical Characteristics 
1-Vessel Disease 2-Vessel Disease 3-Vessel Disease 
(n - 7,604) (n - 2,587) (n = 592) p Value 
Age (yr) 57 = 10 59 + 11 62 ± 11 <0.0001 
Female gender 28% 23% 21% <0.0001 
Diabetes 12% 16% 23% <0.000l 
Hypertension 42% 46% 53% <0.0001 
Prior MI 30% 43% 48% <0.0001 
Class Ili or IV angina 61% 64% 66% 0.0015 
Emergent CABG for unstable angina 3.3% 3.7% 4.6% 0.18 
Congestive failure 2.2% 3.5% 4.5% <0.0001 
Height (cm) 173 +_ 12 174 + 15 175 _+ 19 0.013 
Weight (kg) 80 _+ 15 81 _+ 15 82 _+ 15 0.029 
Body surface area (m-') 1.9 +_ 0.2 1.9 _+ 0.2 2.0 _+ 0.2 0.003 
Data presented are mean value + SD or percent of patients. CABG - coronary, artery bypass graft surgery. 
two-vessel disease and 52% for three-vessel disease (p < 
0.0001, two- vs. three-vessel disease). Complete revasculariza- 
tion was achieved in most patients with one-vessel disease, but 
in only a minority of patients with two-vessel disease and rarely 
in those with three-vessel disease (p < 0.0001, two- vs. 
three-vessel disease). The number of vessels dilated increased 
from one to two and from two to three (p < 0.0001, two- vs. 
three-vessel disease). In this largely stable, first intervention 
population including patients from the start of the Emory 
experience and to its end in 1991, only a small percent of new 
devices were used. Use of devices increased from 0 during 1980 
to 1983 to 0.5% during 1984 to 1989 and to 9.3% during 1990 
to 1991 (p < 0.0001). Emergency coronary, surgery increased 
from 1.7% for one-vessel disease to 3.2% for three-vessel 
disease (p = NS, two- vs. three-vessel disease). Q wave 
myocardial infarctions could not be shown to vary significantly 
with severity of disease. The mortality rate increased from 
0.2% for one-vessel disease to 0.4% for two-vessel and to 1.2% 
for three-vessel disease (p = 0.020, two- vs. three-vessel 
disease). Angina at the time of follow-up varied slightly with 
severity of disease. 
From the variables displayed in Tables 1 and 2, the univa- 
riate and multivariate correlates of in-hospital death are 
displayed in Table 3. The univariate correlates were increased 
number of vessels diseased, lower ejection fraction, emergent 
dilation for unstable angina, short stature, older age, female 
gender, lower body surface area, lower weight, congestive 
failure, severe angina and previous myocardial infarction. The 
Table 2. Angiographic Characteristics and Outcome 
1 -Vessel 2-Vessel 3-Vessel 
Disease Disease Disease p Value 
Ejection fraction (q~) 50 ± 11 56 + 12 56 _+ 12 <0.000l 
Site characteristics of 1st site 
Artery. size (mm) 2.9 + 0.6 2.9 + 0.7 2.8 +- 0.6 0.0167 
Preangioplasty % diameter stenosis 75 + 14 77 _+ 14 77 _+ 12 <0.0001 
Postangioplasty % diameter stenosis 26 ~ 16 27 _+ 18 29 _+ 20 <0.0001 
LAD dilation 56% 48% 45% <0.0001 
Proximal LAD dilation 44% 32% 26% <0.0001 
Multisite 15% 43% 52% <0.0001 
Complete revascularization 84% 25% 5% <0.0001 
Vessels dilated <0.0001 
1 vessel 99% 69% 66% 
2 vessels 1% 30% 28% 
3 vessels 0 0.4% 6% 
New devices 2.3% 2.2% 3.7% 0.030 
Angiographic success in dilating all 909~ 86% 81% <0.0001 
lesions attempted 
Emergent coronary bypass urgery' 1.7% 3.0% 3.2% 0.0001 
Q wave MI 0.8% 0.9% 0.2% 0.19 
Death 0.2% 0.4% 1.2% <0.0001 
Angina at follow-up 30% 28% 33% <0.0001 
Data presented are mean value +_ SD or percent of patients. LAD = left anterior descending coronary artery; MI = 
myocardial infarction. 
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Table 3. Correlates of In-Hospital Death 
No. of Mortalib, 
Deaths Rate OR 
Univariate Analysis 
Multivariate Analysis 
(n = 10,404; 28 deaths) 
95% CI p Value OR 95% CI p Value 
Vessels diseased 
1 Vessel 12 0.2 1.00 
2 Vessels 11 0.4 2.70 1.19-6.13 
3 Vessels 7 1.2 7.57 2.97-19.30 
Height (in.) <0.0001 
<65 15 0.9 1.00 
65-70 4 0.1 0.15 0.06-0.35 
>70 3 0.1 0.09 0.03- 0.30 
Ejection fraction (%) 0.0001 
>50 I 1 0.9 1.00 
->50 11 0.2 0.19 0.09-0.41 
Unstable angina 0.004 
Absent 25 0.2 1.00 
Present 5 1.3 5.63 2.14 14.79 
Age (yr) <0.0001 
<60 6 0.1 1.00 
60-70 10 0.3 2.66 0.94-7.47 
>70 14 1.0 9.32 3.61-24.05 
Gender <0.0001 
Men 9 0.1 1.00 
Women 21 0.7 6.55 3.00 14.32 
Body surface area (m 2) <0.0001 
<1.7 10 0.8 1.00 
1.7-1.8 6 0.6 0.72 0.26 1.99 
1.8 6 0.1 0 .10  0.038-0.29 
Weight (lb) 0.0094 
<150 10 0.6 1.00 
150-175 7 0.3 0.44 0.17-l.15 
>175 6 0.1 0.21 0.08-0.58 
Congestive heart failure 0.0067 
Absent 24 11.2 1.(10 
Present 4 1,4 6.15 2.12-17.84 
Angina class 0.0036 
0-1I 4 0,1 1.00 
III or IV 25 0,4 3.86 1.34 11.10 
Prior MI 0.032 
Absent 14 0,2 1.00 
Present 16 0,4 2.20 1.07-4.51 
0.0003 0.015 
1.00 
1.58 0.65-3.85 
4.84 1.83-12.86 
1.00 
0.19 0.08 - 0.45 
0.12 0.03-0.44 
1.00 
0.22 0.10-0.49 
1.00 
4.92 1.79-13.5 
1.00 
1.78 0.62-5.08 
3.14 1.12-8.80 
<0.0001 
0.0004 
0.008 
0.077 
NS 
NS 
NS 
NS 
NS 
NS 
MI = myocardial infarction OR = odds ratio; CI = confidence interval, 
multivariate characteristics were increased number of vessels 
diseased, reduced ejection fraction, emergent dilation for 
unstable angina, short stature and older age. The univariate 
and multivariate strength of association for each variable can 
be noted from the odds ratio. The multivariate odds ratios for 
two- and three-vessel disease (1.58 and 4.84) were lower than 
their univariate odds ratios (2.70 and 7.571, reflecting that part 
of the increased risk of multivessel disease was accounted for 
by other variables. 
Long-term results. From the variables in Tables 1 and 2, 
the univariate and multivariate correlates of death both in- 
hospital and long term after discharge are displayed in Table 4. 
The univariate correlates were multivessel disease, older age, 
congestive heart failure, reduced ejection fraction, diabetes, 
hypertension, severe angina, female gender, previous myocar- 
dial infarction, lower weight, short stature and reduced body 
surface area. The multivariate correlates were multivessel 
disease, older age, congestive heart failure, reduced ejection 
fraction, diabetes, hypertension and severe angina. The 
strength of association may be noted by the hazard ratio. 
Similar to the aforementioned in-hospital results, the long- 
term mortality univariate hazard ratios for two- and three- 
vessel disease (1.66 and 2.75, respectively) were higher than 
that for the multivariate hazard ratios (1.35 and 1.82, respec- 
tively). This finding reflects that part of the increased risk of 
multivessel disease was accounted for by other variables. 
Survival, classified into one-, two- and three-vessel disease, 
is presented in Figure 1. In each group mortality was essen- 
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Table 4. Long-Term Correlates of Death 
Univariate Analysis 
Hazard Ratio 95% CI p Value 
Multivariate Analysis 
(n = 6,318; 296 deaths) 
Hazard Ratio 95% CI p Value 
Vessels diseased <0.0001 
1 Vessel l.li0 
2 Vessels 1.66 1.44 1.91 
3 Vessels 2.75 2.08-3.63 
Age (yr) <0.0001 
<60 1.00 
60 71) 2.48 1.99-3.08 
>70 5.84 4.59 7.42 
Congestive heart failure <0.0001 
Abscnt 1.00 
Present 4.77 3.48-6.55 
Ejection fraction (G) <0.0001 
<511 1.(10 
>50 0.45 0.35-0.57 
Diabetes <0.0001 
Abscnt 1.00 
Present 2.24 1.80-2.79 
Hypertension <0.0001 
Absent 1.i!1) 
Present 1.64 1.36-1.97 
Angina class <0.0001 
0 11 1.00 
11I or IV 1.87 1.53-2.3[) 
Gender 0.0001 
Male 1.(10 
Female 1.48 1.22 1.80 
Prior M1 <0.11001 
Absent l.(10 
Present 1.50 1.24 1.80 
Weight (Ib) (I.02 
< 150 1.00 
150-175 0.91 0.69-1.20 
>175 0.71 0.56-0.93 
Height (in.) 0.05 
<65 1.00 
65 70 I).81) 0.61 1.114 
>70 0.71 11.55- II.93 
Body surface area (m e ) /I.05 
<1.7 1.00 
1.7-1.8 1.[17 0.73-1.55 
> 1.8 0.78 0.59 1.1i3 
1.00 
1.35 1.14-1.60 
1.82 1.29-2.57 
1.00 
2.01 1.74-2.34 
4.04 3.01-5.42 
1.00 
2.67 1.80-3.97 
1.00 
0.51 0.40-0.67 
1.0(J 
1.64 1.24-2.16 
1.00 
1.35 1.06-1.70 
1.00 
1.27 0.99 1.64 
I).0009 
<0.0001 
<0.0001 
<0.0001 
0.0007 
0.013 
0.059 
NS 
NS 
NS 
NS 
NS 
Abbreviations as in Table 3. 
tially linear out to 10 years. The 1-, 5- and 10-year survival was 
0.99, 0.93 and 0.86 for one-vessel disease and 0.97, 0.89 and 
0.76 for 2 vessel disease, respectively. The 1-, 5- and 9-year 
survival was 0.95, 0.83 and 0.70 for three-vessel disease. 
Survival estimated from the previously described Cox model 
analysis, classified into one-, two- and three-vessel disease with 
all other correlates of survival held constant, is presented in 
Figure 2. The survival curves in Figure 2 resemble those in 
Figure 1 but are somewhat closer together because the Cox 
model analysis adjusted for the other correlates, all of which 
increased in severity from one- to three-vessel disease. Kaplan- 
Meier curves displaying freedom from myocardial infarction 
classified into one-, two- and three-vessel disease are presented 
in Figure 3. After a small initial decrease, representing in- 
hospital events (probably related to abrupt closure or early 
restenosis), the curves are largely linear over time. The sepa- 
ration between the curves is significant but not as strong as that 
for survival. Two- and three-vessel disease varies only slightly. 
The 1-, 5- and 10-year freedom from myocardial infarction was 
0.96, 0.89 and 0.83 for one-vessel disease, respectively. The 1- 
and 5-year freedom from myocardial infarction was 0.94 and 
0.85 for two-vessel disease and 0.92 and 0.82 for three-vessel 
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Figure l. Ten-year survival aftcr angioplasty 
for one-, two- and three-vessel discase. 
Survival 
] ~:;: . . . . .  
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0.9 
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0.65 2) Double Vessel Disease 
0.6 3) Triple Vessel Disease P = <.0001 
0.55 
0.5 
Time in Years 
1 2 3 4 5 6 7 10 
Single Vessel Disease 
N-Remaining 7132 6044 4611 3679 3044 2451 2061 1799 1476 1194 635 
Survival t .99 .98 .96 .95 .93 .92 .91 .89 .88 .86 
Deaths 0 102 156 204 248 293 331 360 386 405 418 
Double Vessel Disease 
N Remaining 2433 2078 1501 1091 860 654 525 386 235 137 60 
Survival l .97 .96 .94 .92 .89 .88 .85 .82 .79 .76 
Deaths 0 61 87 116 137 156 166 183 191 198 201 
Tr~nle Vessel Disease 
Remaining 543 456 306 205 144 93 66 48 34 14 
Survival I .95 .93 .90 .86 .83 .77 .73 .73 .70 
Deaths 0 26 35 42 49 54 60 63 63 64 
disease, respectively. Freedom from coronary bypass urgery is 
displayed in Figure 4. The curves reveal three components: 1)
an initial decrease reflects in-hospital events; 2) frequent 
continuing events over 6 months during the period of resten- 
osis; 3) events continuing to occur thereafter at a somewhat 
slower rate. The need for coronary bypass urgery was related 
to severity of disease. The 1-, 5-, and 10-year freedom from 
coronary, bypass urgery was 0.92, 0.87 and 0.77 for one-vessel 
disease and 0.89, 0.79 and 0.58 for two-vessel disease, respec- 
tively. The 1- and 5-year freedom from coronary bypass urgery 
was 0.86 and 0.73 for three-vessel disease, respectively. Free- 
dom from repeat angioplasty is displayed in Figure 5. The 
Figure 2. Ten-year survival estimated from 
Cox model analysis for one-, two- and three- 
vessel disease with all other correlates of 
survival held constant. 
Corrected 
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Figure 3. Ten-year freedom from myocar- 
dial infarction after angioplasty for one-, 
two- and three-vessel disease. 
separation between these curves is much less than that for 
coronary bypass urgery. The curves display two phases: 1) the 
first 6 months during the period of restenosis, and 2) continu- 
ing events over time. The 1-, 5- and 10-year freedom from 
repeat angioplasty was 0.80, 0.69 and 0.58 for one-vessel 
disease and 0.77, 0.61 and 0.45 for two-vessel disease, respec- 
tively. The 1-, 5- and 9-year freedom from repeat angioplasty 
was 0.73, 0.61 and 0.46 for three-vessel disease, respectively. 
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Figure 4. Ten-year freedom from coronary 
bypass urgery after angioplasty for one-, two- 
and three-vessel disease. 
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Figure 5. Ten-year f eedom from additional 
angioplasty for one-, two- and three-vessel 
disease. 
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Discuss ion  
Coronary artery disease is often considered in terms of the 
number of epicardial vessels obstructed. In the present study 
we showed that the number of vessels diseased isa correlate of 
in-hospital and long-term mortality as well as a correlate of 
long-term myocardial infarction and need for subsequent 
revascularization. We also showed that angioplasty is used 
infrequently for three-vessel disease. 
Previous studies. The effect of number of vessels diseased 
on mortality after angioplasty has been reviewed previously 
(9-11). In one of the first of these studies Vlietstra et al. (9) 
compared outcome of angioplasty in261 patients, 100 of whom 
had multivessel disease. This somewhat early and thus some- 
what limited study gave impetus to further study of angioplasty 
in multivessel disease. Reeder et al. (12) reviewed outcome 
from the National Heart, Lung, and Blood Institute (NHLBI) 
1977-1982 data base of 286 patients with multivessel disease. 
Completeness of revascularization was not an independent 
correlate of mortality. At 2 years the results were similar in 
terms of mortality, freedom from myocardial infarction and 
additional revascularization to the present study. In the 
NHLBI 1985-1986 registry (13), 1,801 patients were followed 
up for 1 year. There were 838 patients with single-vessel 
disease and 963 with multivessel disease. The mortality rate 
was 1.8% for single-vessel and 4.5% for multivessel disease. 
The incidence of myocardial infarction was 5.4% and 8.8% and 
the need for coronary bypass urgery 10.7% vs. 15.3%. The 
need for additional angioplasty was 18.1% in single-vessel 
versus 18.8% in multivessel disease. These data are very similar 
to the 1-year event rates in the present study (see tabulations 
at the bottom of Fig 1 to 4). The multivariate hazard ratio for 
multivessel compared with single-vessel disease was 1.70 for 
death, 1.53 for myocardial infarction and 1.66 for coronary 
bypass surgery. Ten-year follow-up data for patients with 
multivessel versus single-vessel disease have previously been 
published for Gruentzig's original Zurich experience (14,15). 
The 10-year survival rate was 95% for single-vessel and 81% 
for multivessel disease. Survival and event-free survival is 
probably slightly better than that presented in that series, 
which may reflect selection of patients in the original Zurich 
experience. To our knowledge, the current study is larger than 
any previous tudy, with long-term follow-up period as long as 
any previous study comparing long-term outcome of angio- 
plasty in single-vessel and multivessel disease. 
Choice of therapy by severity of disease. There are differ- 
ent choices for appropriate therapy for single-vessel and 
multivessel disease. Single-vessel disease may be treated either 
medically or with interventional techniques in the coronary 
arteries The role for coronary bypass urgery in single-vessel 
disease is limited. Double-vessel disease may be treated with 
medical therapy, intervention in the coronary arteries or 
coronary bypass surgery, depending on the clinical circum- 
stances and anatomic distribution of disease. Symptomatic 
three-vessel disease remains largely a surgical disease, al- 
though improved medical therapy with careful control of 
serum lipid levels as well as improved interventional tech- 
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niques may further limit coronary bypass urgery. In the one 
trial of angioplasty versus medical therapy (16), there was 
prolongation of treadmill time and reduction of angina in 
patients with coronary angioplasty. The trial did not have 
sufficient power to consider death or myocardial infarction. 
Comparison of angioplasty and coronary bypass surgery. 
There are increasing number of published reports comparing 
angioplasty with coronary bypass urgery for multivessel dis- 
ease. Several nonrandomized studies (17-19) have shown no 
difference regarding death or myocardial infarction but more 
additional revascularization procedures inpatients undergoing 
angioplasty. There are at least six randomized studies compar- 
ing multivessel angioplasty with coronary bypass urgery. Re- 
ports from five of these trials--Argentine Randomized Trial of 
Percutaneous Transluminal Coronary Angioplasty Versus Cor- 
onary Artery Bypass Surgery (ERACI) (20) from Argentina, 
the Coronary Artery Bypass Revascularization I vestigation 
(CABRI) (21), German Angioplasty Bypass Investigation 
(GABI) (22) and Randomized Intervention Treatment of 
Angina (RITA) (23) from Europe and the Emory Angioplasty 
Surgery Trial (EAST) (24) from Emory University--have 
reported no difference in death or myocardial infarction at 1 to 
3 years but more revascularization procedures inpatients who 
underwent angioplasty. Patients undergoing angioplasty also 
have more angina at follow-up. Compared with the present 
series (see two- and three-vessel disease data in Fig. 1, 4 and 5), 
the 3-year esults in EAST were similar to the 3-year survival 
rate in the angioplasty arm of 93%, freedom from coronary 
bypass urgery of 78% and freedom from additional angio- 
plasty of 59%. The results of GABI were also similar, with a 
1-year survival rate of 98%, freedom from coronary bypass 
surgery of 79% and freedom from additional angioplasty of 
74%. More detailed comparisons that include economics, 
results of the larger Bypass Angioplasty Revascularization 
Investigation (BARI) (25) and meta-analyses of these trials 
may be expected over the next several years. 
In choosing a form of revascularization, the ability to 
achieve complete revascularization may be a decisive lement 
in decision making. In the EAST trial (24,26) there was more 
complete revascularization in the surgical arm initially and at 
1- and 3-year follow-up. Complete revascularization has clearly 
been shown to be important in surgical series (27-29). Com- 
plete revascularization has not been shown to be as important 
prognostically after angioplasty (12,30,31). We previously 
showed (32) in matched patients with two-vessel disease that 
complete revascularization correlated with survival after coro- 
nary surgery but not after angioplasty. These results are 
compatible with different approaches by surgeons and angio- 
plasty operators: Angioplasty operators eek to revascularize 
the more important lesions, and surgeons bypass all possible 
hemodynamically significant obstructions. 
Clinical series, randomized trials and medical decision 
making. In deciding on whether to perform revascularization 
multiple factors must be taken into account. Clearly, each 
patient must be considered individually, with clinical setting 
and angiographic haracteristics taken into account. There- 
after, data from clinical trials and descriptive studies, such as 
the present one, may be considered together. By eliminating 
selection bias between forms of therapy, clinical trials offer the 
best method of comparing two forms of therapy. The descrip- 
tive outcome studies can have much larger datasets, permitting 
improved precision in predicting prognosis. This is especially 
true when examining subsets of patients or performing detailed 
multivariate analyses, uch as that presented here. Such mul- 
tivariate models can be used to create computer programs to 
predict in-hospital outcome or graphical estimates of survival 
or freedom from events based on the values of clinical 
variables (33). The descriptive studies can also be all inclusive. 
Thus, the descriptive studies may be compared with random- 
ized trials to ensure that the randomized trials do not have a 
severely restricted ataset that limits generalizability. This may 
occur in clinical trials when either exclusion criteria or system- 
atic failure to randomize many eligible patients results in many 
patients being eliminated from the study. Nonetheless, all data 
on outcome of procedures have a bias when they are applied to 
patients who have not yet undergone the procedure. Finally, 
evidence of etficacy, even efficacy compared with another form 
of therapy, may often not be sufficient for decision-making 
purposes. Thus, we can expect cost-effectiveness valuations to 
become increasingly important. 
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